The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release.
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results